Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Gains from Investment Securities: 2013-2025

Historic Gains from Investment Securities for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to $19,000.

  • Coherus Oncology's Gains from Investment Securities fell 93.93% to $19,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $339,000, marking a year-over-year decrease of 81.00%. This contributed to the annual value of $28.7 million for FY2024, which is 21.33% up from last year.
  • Per Coherus Oncology's latest filing, its Gains from Investment Securities stood at $19,000 for Q3 2025, which was down 55.81% from $43,000 recorded in Q2 2025.
  • Coherus Oncology's Gains from Investment Securities' 5-year high stood at $2.8 million during Q1 2023, with a 5-year trough of $10,000 in Q4 2024.
  • Over the past 3 years, Coherus Oncology's median Gains from Investment Securities value was $313,000 (recorded in 2024), while the average stood at $497,273.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first surged by 3,582.61% in 2022, then slumped by 96.93% in 2024.
  • Coherus Oncology's Gains from Investment Securities (Quarterly) stood at $23,000 in 2021, then soared by 3,582.61% to $847,000 in 2022, then crashed by 61.51% to $326,000 in 2023, then tumbled by 96.93% to $10,000 in 2024, then plummeted by 93.93% to $19,000 in 2025.
  • Its Gains from Investment Securities was $19,000 in Q3 2025, compared to $43,000 in Q2 2025 and $267,000 in Q1 2025.